Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company’s once or twice-yearly GLP-1 (semaglutide) implant ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...

Just because a research project sounds like a waste of money to people who know nothing of the topic, doesn’t mean it won’t ...

Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

Vivani Medical, Inc. ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the successful administration of its ...

Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the ...

Vivani also expects the results to support the potential application of a GLP-1 (exenatide) implant for type 2 diabetes and other diseases. How to Spot the Market Bottom: Matt Maley has navigated ...

The device, dubbed NPM-115, is a miniature sub-dermal implant that delivers exenatide, a glucagon-like peptide-1 receptor ...

Vivani Medical will spin off Cortigent, its neurostimulation business, as an independently publicly traded company as it ...